BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20963907)

  • 1. [gamma-Seminoprotein (gamma-Sm)].
    Miyahara S
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():743-6. PubMed ID: 20963907
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gamma-seminoprotein (gamma-Sm)].
    Miyahara S
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():698-701. PubMed ID: 16149615
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer].
    Akino H; Suzuki Y; Okada K
    Nihon Rinsho; 1998 Aug; 56(8):2003-5. PubMed ID: 9750496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
    Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate-specific antigen in cancer and benign prostatic hyperplasia].
    Kushlinskiĭ NE; Liubimova NV; Gorilovskiĭ LM
    Biull Eksp Biol Med; 1997 Sep; 124(9):327-30. PubMed ID: 9445619
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum gamma-seminoprotein determination in prostatic cancer.
    Shimazaki J; Akimoto S; Akakura K; Yoshiki T; Yoshida O; Okada K; Matsuoka K; Noda S; Eto K
    Hinyokika Kiyo; 1991 Apr; 37(4):341-7. PubMed ID: 1716404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 9. [Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay].
    Chichibu K; Kuroe K; Hashimoto C; Goto S
    Rinsho Byori; 1995 Nov; 43(11):1153-8. PubMed ID: 8551680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benign prostatic hypertrophy with high levels of gamma-seminoprotein (gamma-Sm), prostate specific antigen: report of two cases].
    Asakawa M; Yasumoto R; Kamizuru M; Maekawa M
    Hinyokika Kiyo; 1988 Dec; 34(12):2189-91. PubMed ID: 2467544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
    Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
    Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm)].
    Tsukamoto T; Kumamoto Y; Yamazaki K; Umehara T; Miyao N; Ohmura K; Iwazawa M
    Hinyokika Kiyo; 1988 Jun; 34(6):987-95. PubMed ID: 2464917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Gamma-seminoprotein--a new tumour marker in prostatic cancer?
    Scheit KH
    Br J Urol; 1991 Sep; 68(3):331-2. PubMed ID: 1717099
    [No Abstract]   [Full Text] [Related]  

  • 15. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
    Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
    [No Abstract]   [Full Text] [Related]  

  • 17. Ductal adenocarcinoma of the prostate.
    Shazer RL; Luthringer D; Agus DB; Gross ME
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):393-5; discussion 396. PubMed ID: 16163211
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gamma-Sm].
    Miyahara S
    Nihon Rinsho; 1999 Dec; 57 Suppl():523-5. PubMed ID: 10778180
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases].
    Uchijima Y; Yoshida K; Saitoh H
    Hinyokika Kiyo; 1991 Oct; 37(10):1255-60. PubMed ID: 1721770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of tumor markers in prostatic cancer].
    Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
    Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.